doi: 10.1002/cmdc.200900155.
Meropenem-clavulanate: a new strategy for the treatment of tuberculosis?
Affiliations
- PMID: 19462395
- DOI: 10.1002/cmdc.200900155
Item in Clipboard
Meropenem-clavulanate: a new strategy for the treatment of tuberculosis?
ChemMedChem.
2009 Jul.
Abstract
The Great White Plague: Mycobacterium tuberculosis, the bacteria causing tuberculosis, is a continuing threat to global health through the emergence of resistant strains and the lack of novel therapeutic agents. Recently reported results on this important work are highlighted.
Similar articles
-
Beta-lactamases of Mycobacterium tuberculosis and Mycobacterium kansasii.Microbiologia. 1997 Sep;13(3):331-6. Microbiologia. 1997. PMID: 9353752 Review.
-
Clinical use of the meropenem-clavulanate combination for extensively drug-resistant tuberculosis.Int J Tuberc Lung Dis. 2012 Apr;16(4):558-60. doi: 10.5588/ijtld.11.0414. Int J Tuberc Lung Dis. 2012. PMID: 22325421
-
Can inhibitor-resistant substitutions in the Mycobacterium tuberculosis β-Lactamase BlaC lead to clavulanate resistance?: a biochemical rationale for the use of β-lactam-β-lactamase inhibitor combinations.Antimicrob Agents Chemother. 2013 Dec;57(12):6085-96. doi: 10.1128/AAC.01253-13. Epub 2013 Sep 23. Antimicrob Agents Chemother. 2013. PMID: 24060876 Free PMC article.
-
Meropenem/clavulanate and linezolid treatment for extensively drug-resistant tuberculosis.Pediatr Infect Dis J. 2011 Sep;30(9):812-3. doi: 10.1097/INF.0b013e3182154b05. Pediatr Infect Dis J. 2011. PMID: 21378593
-
Peptide deformylase--a promising therapeutic target for tuberculosis and antibacterial drug discovery.Expert Opin Ther Targets. 2009 Jul;13(7):753-65. doi: 10.1517/14728220903005590. Expert Opin Ther Targets. 2009. PMID: 19530983 Review.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
